| |
TRG 1
|
OR (95% CI)a
|
Downstaging
|
OR (95% CI)a
|
|---|
| |
n
|
(%)
|
n
|
(%)
|
|---|
|
Sex
|
|
Man
|
13
|
(26.0)
|
Reference
|
34
|
(70.8)
|
Reference
|
|
Woman
|
7
|
(26.9)
|
1.67 (0.60–4.62)
|
18
|
(72.0)
|
0.90 (0.21–3.88)
|
|
Age (years)
|
|
< 55
|
5
|
(29.4)
|
Reference
|
12
|
(70.6)
|
Reference
|
|
55–64
|
5
|
(18.5)
|
0.36 (0.10–1.27)
|
14
|
(56.0)
|
0.37 (0.07–1.99)
|
|
65–74
|
6
|
(31.6)
|
1.01 (0.26–3.85)
|
16
|
(84.2)
|
2.93 (0.40–21.37)
|
|
≥ 75
|
4
|
(30.8)
|
0.85 (0.20–3.56)
|
10
|
(83.3)
|
2.75 (0.34–22.48)
|
|
Distance EAS (mm)
|
|
< 60
|
9
|
(23.7)
|
Reference
|
29
|
(80.6)
|
Reference
|
|
≥ 60
|
8
|
(27.6)
|
0.88 (0.30–2.55)
|
17
|
(58.6)
|
0.12 (0.02–0.69)
|
|
Unknown
|
3
|
(33.3)
|
1.026 (0.22–7.12)
|
6
|
(75.0)
|
0.15 (0.01–2.43)
|
|
cT
|
|
cT2
|
2
|
(40.0)
|
Reference
|
3
|
(100.0)
|
-
|
|
cT3
|
17
|
(27.0)
|
0.29 (0.02–4.14)
|
42
|
(67.7)
|
-
|
|
cT4
|
1
|
(12.5)
|
0.29 (0.02–5.68)
|
7
|
(87.5)
|
-
|
|
cN
|
|
cN0
|
4
|
(33.3)
|
Reference
|
8
|
(66.7)
|
Reference
|
|
cN1
|
10
|
(25.6)
|
0.59 (0.16–2.23)
|
25
|
(67.6)
|
0.39 (0.06–2.60)
|
|
cN2
|
6
|
(24.0)
|
0.77 (0.18–3.34)
|
19
|
(79.2)
|
1.14 (0.17–7.82)
|
|
MRF involvment
|
|
No
|
6
|
(17.7)
|
Reference
|
31
|
(79.5)
|
Reference
|
|
Yes
|
14
|
(33.3)
|
0.34 (0.11–1.01)
|
21
|
(61.8)
|
0.29 (0.07–1.18)
|
|
Single dose intensity
|
|
2.1
|
3
|
(18.8)
|
Reference
|
12
|
(80.0)
|
Reference
|
|
2.16
|
9
|
(37.5)
|
1.45 (0.36–5.84)
|
15
|
(62.5)
|
0.16 (0.02–1.47)
|
|
≥ 2.2
|
8
|
(22.2)
|
1.45 (0.39–5.38)
|
25
|
(73.5)
|
1.14 (0.14–9.25)
|
-
aAdjusted for all variables reported in the table
